I-Mab Past Earnings Performance
Past criteria checks 0/6
I-Mab's earnings have been declining at an average annual rate of -22.9%, while the Biotechs industry saw earnings growing at 12.3% annually. Revenues have been declining at an average rate of 14.2% per year.
Key information
-22.9%
Earnings growth rate
61.7%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | -14.2% |
Return on equity | -85.3% |
Net Margin | -5,302.0% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
I-Mab: Trading Below Net Cash With Multiple Upside Options
Feb 18We're Keeping An Eye On I-Mab's (NASDAQ:IMAB) Cash Burn Rate
Feb 08I-Mab: Another CD47 Inhibitor Biotech With Great Potential
Sep 27I-Mab gets Chinese nod to start phase 3 combo treatment trial for myelodysplastic syndrome
Sep 13I-Mab Biopharma Non-GAAP EPADS of -$1.54, revenue of $7.74M
Aug 30I-Mab and senior executives may buy $40M worth of shares; stock up 10%
Aug 23Newsflash: I-Mab (NASDAQ:IMAB) Analysts Have Been Trimming Their Revenue Forecasts
Aug 20I-Mab doses first patient in phase 1 trial of TJ-CD4B in solid tumors in China
Jul 22I-Mab Valuation Offers A Biotech Investment Opportunity
Jun 23Companies Like I-Mab (NASDAQ:IMAB) Are In A Position To Invest In Growth
May 24I-Mab Shaken By Management Moves, Merger Talk And Delisting Threat
May 06Bearish: Analysts Just Cut Their I-Mab (NASDAQ:IMAB) Revenue and EPS estimates
Apr 01I-Mab Founder Retakes Reins In Latest Shakeup Ahead Of Commercialization Phase
Jan 03I-Mab Gets Boost From Latest Industry Signals On New Cancer Treatment
Oct 14Drug Maker I-Mab Wins Plaudits As Analysts Urge Caution On Soaring Stock
Jul 02I-Mab adds gastrointestinal oncology expert Andrew Zhu to Scientific Advisory Board
Jun 21I-Mab in talks seeking a billion-dollar deal for cancer therapy: Bloomberg
Jun 14Revenue & Expenses BreakdownBeta
How I-Mab makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 28 | -1,466 | 453 | 811 |
30 Sep 23 | -113 | -1,802 | 513 | 855 |
30 Jun 23 | -254 | -2,138 | 573 | 899 |
31 Mar 23 | -238 | -2,275 | 647 | 902 |
31 Dec 22 | -222 | -2,412 | 720 | 905 |
30 Sep 22 | -50 | -2,357 | 790 | 989 |
30 Jun 22 | 122 | -2,302 | 850 | 1,073 |
31 Mar 22 | 105 | -2,317 | 875 | 1,143 |
31 Dec 21 | 88 | -2,332 | 900 | 1,213 |
30 Sep 21 | 1,596 | -662 | 758 | 1,189 |
30 Jun 21 | 1,560 | -23 | 674 | 1,135 |
31 Mar 21 | 1,552 | 224 | 538 | 1,060 |
31 Dec 20 | 1,543 | 471 | 402 | 985 |
30 Sep 20 | 0 | -952 | 383 | 960 |
30 Jun 20 | 15 | -1,211 | 251 | 1,018 |
31 Mar 20 | 23 | -1,348 | 453 | 929 |
31 Dec 19 | 30 | -1,485 | 655 | 840 |
30 Sep 19 | 40 | -1,227 | 608 | 690 |
30 Jun 19 | 47 | -1,093 | 622 | 488 |
31 Mar 19 | 51 | -748 | 344 | 457 |
31 Dec 18 | 54 | -403 | 66 | 426 |
31 Dec 17 | 12 | -298 | 25 | 267 |
Quality Earnings: IMAB is currently unprofitable.
Growing Profit Margin: IMAB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IMAB is unprofitable, and losses have increased over the past 5 years at a rate of 22.9% per year.
Accelerating Growth: Unable to compare IMAB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMAB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: IMAB has a negative Return on Equity (-85.31%), as it is currently unprofitable.